Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70329 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Brian H Kushner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glycolipids, Granulocyte-Macrophage Colony-Stimulating Factor, Cancer Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Katie's Find A Cure Fund, Rhyan Loos Family Fund, NCI NIH HHS.
Abstract (Originalsprache)
Naxitamab + GM‐CSF was effective against chemo‐resistant high‐risk neuroblastoma (HR‐NB), leading to approval by the Food and Drug Administration. We now describe toxicity and outcome of patients treated in first complete remission (CR) with naxitamab plus novel dosing of GM‐CSF (nGM‐CSF), initiated in February 2021, based on pharmacologic data. Treatment also included an anti‐NB vaccine but no prior myeloablative therapy (MAT). This retrospective study covers all first CR HR‐NB patients who started the novel naxitamab + nGM‐CSF regimen from February 22, 2021 to December 11, 2023. As before, naxitamab (3 mg/kg) was infused on days 1–3–5 (i.e., 3 doses/cycle). Previously, priming doses of GM‐CSF 250 μg/m 2 /day were subcutaneously administered ×5 (days −4 to 0), followed by step‐up to 500 μg/m 2 /day ×5 (days 1 to 5), but now priming doses were ×3 (days −2 to 0) and stepped‐up dosing was ×7 (days 1 to 7), that is, through 2 days after the last dose of naxitamab. After completing antibody treatment (5 monthly cycles), patients could receive vaccine. Event‐free survival (EFS) and overall survival (OS) were calculated from start of naxitamab + nGM‐CSF. Forty‐three patients received 157 cycles. Acute toxicities were generally manageable, allowing outpatient treatment. Stepped‐up dosing and extended administration of GM‐CSF had no associated toxicity, hematological or otherwise. Human anti‐human antibody developed in 5/43 (12%) patients. Thirty‐four (79%) patients received the vaccine; 9 did not due to relapse ( n = 4) and parental choice ( n = 5). EFS/OS rates at 24 months were 88%/95% and at 36 months were 80%/95%. Naxitamab + nGM‐CSF is a good option to consolidate first CR of HR‐NB patients, including those who did not undergo MAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Brian H Kushner, Shakeel Modak
Förderung
- Katie's Find A Cure Fund
- Rhyan Loos Family Fund
- NCI NIH HHS
- Band of Parents Foundation
- Robert Steel Foundation
- National Cancer Institute
- Robert K Steel Family Foundation
Zitieren
APA
Kushner, B. H., White, C., Mauguen, A., Cardenas, F. I., Basu, E. M., Wei, W., Kramer, K., & Modak, S. (2026). Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission. International Journal of Cancer. https://doi.org/10.1002/ijc.70329
Vancouver
Kushner BH, White C, Mauguen A, Cardenas FI, Basu EM, Wei W, et al. Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission. International Journal of Cancer. 2026. doi:10.1002/ijc.70329
BibTeX
@article{Kushner2026,
author = {Kushner, Brian H and White, Charlie and Mauguen, Audrey and Cardenas, Fiorella Iglesias and Basu, Ellen M and Wei, Wei and Kramer, Kim and Modak, Shakeel},
title = {Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70329}
}
EUVIMED